<?xml version="1.0" encoding="UTF-8"?>
<results title="tropicalVirus">
 <result pre="6789597 doi: 10.3390/ph12030101pharmaceuticals-12-00101 : Review Antiviral Agents in Development for" exact="Zika" post="Virus Infections BazMariana*BoivinGuy*[], *Correspondence: Mariana.Baz@crchudequebec.ulaval.ca (M.B.); Guy.Boivin@crchul.ulaval.ca (G.B.); Tel.:"/>
 <result pre="Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract In 1947," exact="Zika" post="virus (ZIKV), a mosquito-borne flavivirus was identified in Uganda"/>
 <result pre="alarm due to its increased virulence and rapid dissemination. Importantly," exact="ZIKV" post="infections have been associated with severe neurological complications such"/>
 <result pre="still no approved specific antiviral drug for the treatment of" exact="ZIKV" post="infections. Herein, we review several anti ZIKV candidates including"/>
 <result pre="the treatment of ZIKV infections. Herein, we review several anti" exact="ZIKV" post="candidates including drugs targeting both the virus (structural proteins"/>
 <result pre="both the virus (structural proteins and enzymes) and cellular elements." exact="Zika" post="virus antiviral agents small molecules virus targets host targets"/>
 <result pre="molecules virus targets host targets repurposing pre-clinical studies 1. Introduction" exact="Zika" post="virus (ZIKV) is a member of the Flaviviridae family"/>
 <result pre="clusters [1]. Mosquito-borne flaviviruses such as ZIKV, dengue virus (DENV)," exact="West Nile" post="virus (WNV), yellow fever virus (YFV), and Japanese encephalitis"/>
 <result pre="the last decade since their global incidence has grown dramatically." exact="ZIKV" post="(strain MR 766) was first isolated in 1947 [3]"/>
 <result pre="from serum samples of a Rhesus monkey during investigation on" exact="YFV" post="in the Zika forest of Uganda. In 1948, the"/>
 <result pre="of a Rhesus monkey during investigation on YFV in the" exact="Zika" post="forest of Uganda. In 1948, the virus was isolated"/>
 <result pre="in the same forest [4]. The first human cases of" exact="ZIKV" post="infections were reported in Africa in the 1950s [5]"/>
 <result pre="Cook Islands in 2013 and 2014 [6]. In May 2015," exact="ZIKV" post="spread across the Pacific Ocean and was introduced in"/>
 <result pre="subnational areas, and became a public health problem worldwide [8]." exact="ZIKV" post="infection is usually asymptomatic or produces a relatively mild"/>
 <result pre="recovery [6]. However, during the 2015 epidemics in South America," exact="ZIKV" post="became a global health threat, showing increased virulence, rapid"/>
 <result pre="newborns and a remarkable increase in Guillain–Barré syndrome cases [8,9]." exact="ZIKV" post="is transmitted to people primarily through the bite of"/>
 <result pre="different tissues including reproductive tissues and organs [12,13,14]. In males," exact="ZIKV" post="can infect testes, the prostate, and seminal vesicles [14,15],"/>
 <result pre="cells from the placenta [14,16]. Therefore, direct human–to–human transmission of" exact="ZIKV" post="can occur perinatally [17], sexually [18,19], and through breastfeeding"/>
 <result pre="is no vaccine or drug licensed to prevent or treat" exact="ZIKV" post="infections. The aim of this review article is to"/>
 <result pre="anti-ZIKV agents. 2. Genome and Replicative Cycle The genome of" exact="ZIKV" post="(strain MR 766) comprises a 10.8-kb single-stranded positive-sense RNA"/>
 <result pre="modulation of host defense mechanism [35]. The replicative cycle of" exact="ZIKV" post="is similar to other known flaviviruses (Figure 2). Briefly,"/>
 <result pre="the tyrosine-protein kinase receptor AXL, Tyro3, DC-SIGN, and TIM-1, facilitate" exact="ZIKV" post="viral entry [37]. The viral genome is released into"/>
 <result pre="extracellular space. 3. Potential Therapeutic Options for the Treatment of" exact="ZIKV" post="Infection So far, no specific antiviral is approved for"/>
 <result pre="far, no specific antiviral is approved for the treatment of" exact="ZIKV" post="infections. Acetaminophen is usually used to control fever and"/>
 <result pre="infection in children and teenagers [11]. The current search for" exact="ZIKV" post="antiviral options is being conducted through several different approaches"/>
 <result pre="drugs and therapeutic candidates have been discovered or repurposed with" exact="ZIKV" post="activity both in vitro and in pre-clinical studies and"/>
 <result pre="host cell replication. Consequently, they have been extensively evaluated against" exact="ZIKV" post="in cell culture and in animal models. Eyer et"/>
 <result pre="µM for their ability to inhibit cytopathic effects (CPE) of" exact="ZIKV" post="on Vero cells. They found that five of these"/>
 <result pre="and 2’-C-methyluridine (2-CMU), significantly reduced cell death compared to non-treated" exact="ZIKV" post="infected cells with 50% effective concentration (EC50) values ranging"/>
 <result pre="2’-C-methylated nucleosides on the in vitro activity of purified recombinant" exact="ZIKV" post="RdRp [46]. In addition, the viral polymerase inhibitor 7-deaza-2-CMA"/>
 <result pre="and safe for short-term therapy of acute flaviviral diseases, including" exact="WNV" post="[49], and thus represents one of the most promising"/>
 <result pre="ability of favipiravir to inhibit several geographically and temporally different" exact="ZIKV" post="strains in in vitro assays [51,52]. The genetic barrier"/>
 <result pre="pyrimidine synthesis inhibitor such as NITD008 exhibited antiviral activity against" exact="ZIKV" post="in vitro (EC50 = 0.28–0.95 µM) and in A129"/>
 <result pre="active site of NS5 [56] and was shown to inhibit" exact="ZIKV" post="infection and replication in human hepatocellular carcinoma (Huh-7) cells,"/>
 <result pre="varied among different cell types [58]. Interestingly, sequence analysis of" exact="ZIKV" post="isolated from infected cells treated with sofosbuvir showed higher"/>
 <result pre="of viral RNA synthesis [62]. It was found to inhibit" exact="ZIKV" post="replication in Vero cells with EC50 values in the"/>
 <result pre="strain [64]. In addition, treatment of AG129 mice infected with" exact="ZIKV" post="(Malaysian strain, P-6-740) twice daily (BID) with an intramuscular"/>
 <result pre="[65]. Hercik et al. reported the crystal structure of the" exact="ZIKV" post="methyltransferase in complex with the pan-methyltransferase inhibitor sinefungin, an"/>
 <result pre="affinity toward the enzyme for better selectivity and inhibition of" exact="ZIKV" post="replication [68]. However, when this drug was used as"/>
 <result pre="µM) and binding activity (KD of ∼5–10 μM) against the" exact="Zika" post="NS2B-NS3 protease from testing 71 HCV NS3/NS4A inhibitors that"/>
 <result pre="protease, and some of them have been found to inhibit" exact="ZIKV" post="protease activity. Lim et al. evaluated 22 polyphenol compounds"/>
 <result pre="and one natural phenol (curcumin) which were shown to inhibit" exact="Zika" post="NS2B-NS3 protease by binding to a pocket on the"/>
 <result pre="the active site and allosterically affect the structure-activity property of" exact="Zika" post="NS2B-NS3 protease. The EC50 from the flavonoids ranged between"/>
 <result pre="identified eight clinically approved drugs with inhibitory activity on the" exact="ZIKV" post="NS2B-NS3 protease [77]. In addition, the authors further validated"/>
 <result pre="triphosphatase (RTPase) activities. NS3 inhibitors can be used to impede" exact="ZIKV" post="infection. Suramin, an anti-parasitic drug used to treat trypanosomal"/>
 <result pre="but both the release of genomes and the infectivity of" exact="ZIKV" post="were reduced, suggesting that this drug also affects virus"/>
 <result pre="virus biogenesis probably by interfering with glycosylation and maturation of" exact="ZIKV" post="during traffic through the secretory pathway [85]. 3.2. Host-Targeting"/>
 <result pre="group and others demonstrated the inhibitory activity of ribavirin against" exact="ZIKV" post="strains of different geographic origins in several cell lines"/>
 <result pre="type I IFN signaling and are thus highly sensitive to" exact="ZIKV" post="infection with a lethal outcome [89]. Recent studies have"/>
 <result pre="the purine synthesis and immunosuppressive compound, was shown to abolish" exact="ZIKV" post="replication in HeLa (cervical cancer cells) and JEG3 (human"/>
 <result pre="the synthesis of pyrimidines have also been shown to affect" exact="ZIKV" post="replication. Pascoalino et al. screened a library of 725"/>
 <result pre="action. The entire library was screened at 20 µM against" exact="ZIKV" post="infecting Huh7 cells. The authors identified the 6-azauridine (EC50"/>
 <result pre="identified lovastatin, a 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitor, whose activity against" exact="ZIKV" post="was confirmed through a dose-response assay (EC50 = 20.7"/>
 <result pre="antiflaviviral activity of lovastatin was also demonstrated against HCV and" exact="DENV" post="[94,95]. In addition, Sarkey et al., demonstrated that a"/>
 <result pre="nerve diseases such as Guillain–Barré syndrome (GBS), a consequence of" exact="ZIKV" post="infection [96]. Retallack et al. performed the screening of"/>
 <result pre="cytopathic effect in glial cells with low toxicity and reduced" exact="ZIKV" post="infection of U87 cells at an EC50 of 2"/>
 <result pre="chloroquine was able to partially reverse morphological changes induced by" exact="ZIKV" post="in mouse neurospheres [101]. In vitro, chloroquine reduces the"/>
 <result pre="cells, and inhibits virus production and cell death promoted by" exact="ZIKV" post="infection without cytotoxic effects [101]. Saliphenylhalamide (SaliPhe), a viral"/>
 <result pre="vacuolar ATPase and prevents the acidification of endosomes, also inhibits" exact="ZIKV" post="replication in human retinal pigment epithelial (RPE) cells, which"/>
 <result pre="retinal pigment epithelial (RPE) cells, which are natural targets for" exact="ZIKV" post="infection [102] with an EC50 of 1 μM [103]."/>
 <result pre="fully elucidated [104]. In glioblastoma SNB-19 cells, the EC50 against" exact="ZIKV" post="was 0.37 μM based on the measurement of intracellular"/>
 <result pre="[105]. PHA-690509, is an investigational cyclin-dependent kinase inhibitor which inhibited" exact="ZIKV" post="infection with an EC50 value of 1.72 μM [105]."/>
 <result pre="against cell death in multiple neural cell types or inhibit" exact="ZIKV" post="replication. Among them, seliciclib (a purine analog) and RGB-286147"/>
 <result pre="replication. Among them, seliciclib (a purine analog) and RGB-286147 inhibited" exact="ZIKV" post="infection at sub-micromolar concentrations [105]. Studies from Costa et"/>
 <result pre="sub-micromolar concentrations [105]. Studies from Costa et al. showed that" exact="ZIKV" post="has tropism for the central nervous system (CNS) and"/>
 <result pre="neurons, inducing neurodegeneration, neuroinflammation, and ophthalmologic disorders [106]. Neurodegeneration in" exact="ZIKV" post="disease possibly occurs due to the excitotoxicity of glutamate."/>
 <result pre="ifenprodil were found to prevent neuronal cell death caused by" exact="ZIKV" post="under in vitro conditions without reducing viral titers [106]."/>
 <result pre="[106]. Blocking hyperactivation of NMDAR would therefore reduce rates of" exact="Zika" post="virus-induced cell death and help ameliorate neuronal symptoms during"/>
 <result pre="could be used safely to reduce neurological complications associated with" exact="ZIKV" post="infection. 4. Who Benefits from ZIKV Therapies? In immunocompetent"/>
 <result pre="neurological complications associated with ZIKV infection. 4. Who Benefits from" exact="ZIKV" post="Therapies? In immunocompetent individuals, ZIKV infection is asymptomatic or"/>
 <result pre="infection. 4. Who Benefits from ZIKV Therapies? In immunocompetent individuals," exact="ZIKV" post="infection is asymptomatic or produces a relatively mild illness"/>
 <result pre="acetaminophen, anti-histamines, and fluids. However, due to the ability of" exact="ZIKV" post="to infect fetuses and cause severe neurological disease, there"/>
 <result pre="Many FDA approved drugs have been tested for efficacy against" exact="ZIKV" post="and can be repurposed for treating ZIKV infection in"/>
 <result pre="for efficacy against ZIKV and can be repurposed for treating" exact="ZIKV" post="infection in humans. In order to reach the fetus,"/>
 <result pre="vaccine and antiviral drugs for the prevention or treatment of" exact="ZIKV" post="infections. However, there is still no approved vaccine or"/>
 <result pre="physical propertiesTrans. R. Soc. Trop. Med. Hyg.19524652153410.1016/0035-9203(52)90043-612995441 4.HaddowA.J.WilliamsM.C.WoodallJ.P.SimpsonD.I.GomaL.K.Twelve Isolations of" exact="Zika" post="Virus from Aedes (Stegomyia) Africanus (Theobald) Taken in and"/>
 <result pre="MicronesiaN. Engl. J. Med.20093602536254310.1056/NEJMoa080571519516034 7.ZanlucaC.MeloV.C.MosimannA.L.SantosG.I.SantosC.N.LuzK.First report of autochthonous transmission of" exact="Zika" post="virus in BrazilMem. Inst. Oswaldo Cruz201511056957210.1590/0074-0276015019226061233 8.HamelinM.E.BazM.AbedY.CoutureC.JoubertP.BeaulieuE.BelleroseN.PlanteM.MallettC.SchumerG.et al.Oseltamivir-resistant pandemic"/>
 <result pre="of selected Senegalese Aedes spp. mosquitoes (Diptera: Culicidae) to transmit" exact="Zika" post="virusBMC Infect. Dis.20151549210.1186/s12879-015-1231-226527535 11.MussoD.GublerD.J.Zika VirusClin. Microbiol. Rev.20162948752410.1128/CMR.00072-1527029595 12.GourinatA.C.O’ConnorO.CalvezE.GoarantC.Dupont-RouzeyrolM.Detection of"/>
 <result pre="Zika virusBMC Infect. Dis.20151549210.1186/s12879-015-1231-226527535 11.MussoD.GublerD.J.Zika VirusClin. Microbiol. Rev.20162948752410.1128/CMR.00072-1527029595 12.GourinatA.C.O’ConnorO.CalvezE.GoarantC.Dupont-RouzeyrolM.Detection of" exact="Zika" post="virus in urineEmerg. Infect. Dis.201521848610.3201/eid2101.14089425530324 13.CoffeyL.L.PesaventoP.A.KeeslerR.I.SingapuriA.WatanabeJ.WatanabeR.YeeJ.Bliss-MoreauE.CruzenC.ChristeK.L.et al.Zika Virus Tissue"/>
 <result pre="persistence in multiple tissuesPLoS Pathog.201713e100621910.1371/journal.ppat.100621928278237 17.BesnardM.LastereS.TeissierA.Cao-LormeauV.MussoD.Evidence of perinatal transmission of" exact="Zika" post="virus, French Polynesia, December 2013 and February 2014Eurosurveillance20141910.2807/1560-7917.ES2014.19.13.20751 18.ImperatoP.J.The"/>
 <result pre="of a Virus, Mosquitoes, and Human Travel in Globalizing the" exact="Zika" post="EpidemicJ. Commun. Health20164167467910.1007/s10900-016-0177-7 19.FoyB.D.KobylinskiK.C.Chilson FoyJ.L.BlitvichB.J.Travassos da RosaA.HaddowA.D.LanciottiR.S.TeshR.B.Probable non-vector-borne transmission"/>
 <result pre="EpidemicJ. Commun. Health20164167467910.1007/s10900-016-0177-7 19.FoyB.D.KobylinskiK.C.Chilson FoyJ.L.BlitvichB.J.Travassos da RosaA.HaddowA.D.LanciottiR.S.TeshR.B.Probable non-vector-borne transmission of" exact="Zika" post="virus, Colorado, USAEmerg. Infect. Dis.20111788088210.3201/eid1705.10193921529401 20.Dupont-RouzeyrolM.BironA.O’ConnorO.HuguonE.DesclouxE.Infectious Zika viral particles"/>
 <result pre="non-vector-borne transmission of Zika virus, Colorado, USAEmerg. Infect. Dis.20111788088210.3201/eid1705.10193921529401 20.Dupont-RouzeyrolM.BironA.O’ConnorO.HuguonE.DesclouxE.Infectious" exact="Zika" post="viral particles in breastmilkLancet2016387105110.1016/S0140-6736(16)00624-3 21.CalvetG.AguiarR.S.MeloA.S.O.SampaioS.A.de FilippisI.FabriA.AraujoE.S.M.de SequeiraP.C.de MendoncaM.C.L.de OliveiraL.et"/>
 <result pre="breastmilkLancet2016387105110.1016/S0140-6736(16)00624-3 21.CalvetG.AguiarR.S.MeloA.S.O.SampaioS.A.de FilippisI.FabriA.AraujoE.S.M.de SequeiraP.C.de MendoncaM.C.L.de OliveiraL.et al.Detection and sequencing of" exact="Zika" post="virus from amniotic fluid of fetuses with microcephaly in"/>
 <result pre="in Brazil: A case studyLancet Infect. Dis.20161665366010.1016/S1473-3099(16)00095-526897108 22.MussoD.NhanT.RobinE.RocheC.BierlaireD.ZisouK.Shan YanA.Cao-LormeauV.M.BroultJ.Potential for" exact="Zika" post="virus transmission through blood transfusion demonstrated during an outbreak"/>
 <result pre="viral polyproteinProc. Natl. Acad. Sci. USA1990878898890210.1073/pnas.87.22.88982147282 26.WenglerG.CzayaG.FarberP.M.HegemannJ.H.In vitro synthesis of" exact="West Nile" post="virus proteins indicates that the amino-terminal segment of the"/>
 <result pre="for the activation of flaviviral NS3 proteases from dengue and" exact="West Nile" post="virusNat. Struct. Mol. Biol.20061337237310.1038/nsmb107316532006 33.Munoz-JordanJ.L.Sanchez-BurgosG.G.Laurent-RolleM.Garcia-SastreA.Inhibition of interferon signaling by"/>
 <result pre="dengue virusProc. Natl. Acad. Sci. USA2003100143331433810.1073/pnas.233516810014612562 34.RoosendaalJ.WestawayE.G.KhromykhA.MackenzieJ.M.Regulated cleavages at the" exact="West Nile" post="virus NS4A-2K-NS4B junctions play a major role in rearranging"/>
 <result pre="genome organization, expression, and replicationAnnu. Rev. Microbiol.19904464968810.1146/annurev.mi.44.100190.0032452174669 37.HamelR.DejarnacO.WichitS.EkchariyawatP.NeyretA.LuplertlopN.Perera-LecoinM.SurasombatpattanaP.TalignaniL.ThomasF.et al.Biology of" exact="Zika" post="Virus Infection in Human Skin CellsJ. Virol.2015898880889610.1128/JVI.00354-1526085147 38.Van HemertF.BerkhoutB.Nucleotide"/>
 <result pre="in Human Skin CellsJ. Virol.2015898880889610.1128/JVI.00354-1526085147 38.Van HemertF.BerkhoutB.Nucleotide composition of the" exact="Zika" post="virus RNA genome and its codon usageVirol. J.2016139510.1186/s12985-016-0551-127278486 39.LindenbachB.D.RiceC.M.Molecular"/>
 <result pre="Res.200359236114696326 40.BatistaM.N.BragaA.C.S.CamposG.R.F.SouzaM.M.MatosR.P.A.LopesT.Z.CandidoN.M.LimaM.L.D.MachadoF.C.AndradeS.T.Q.et al.Natural Products Isolated from Oriental Medicinal Herbs Inactivate" exact="Zika" post="VirusViruses2019114910.3390/v11010049 41.HaddadJ.G.KoishiA.C.GaudryA.Nunes Duarte Dos SantosC.ViranaickenW.DespresP.El KalamouniC.Doratoxylon apetalum, an Indigenous"/>
 <result pre="Medicinal Plant from Mascarene Islands, Is a Potent Inhibitor of" exact="Zika" post="and Dengue Virus Infection in Human CellsInt. J. Mol."/>
 <result pre="from Mascarene Islands, Is a Potent Inhibitor of Zika and" exact="Dengue" post="Virus Infection in Human CellsInt. J. Mol. Sci.201920238210.3390/ijms20102382 42.collab:"/>
 <result pre="42.collab: Tychan Pte Ltd.Safety and Tolerability of an Antibody Against" exact="Zika" post="Virus (Tyzivumab) in ZIKV Infected Patients. ClinicalTrials.gov. NCT number:"/>
 <result pre="and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in" exact="ZIKV" post="Infected Patients. ClinicalTrials.gov. NCT number: NCT03776695. 2018 Dec. NCT03776695Available"/>
 <result pre="antibodies targeting different epitopes of E protein confer protection against" exact="Zika" post="virus in a neonatal mouse modelEmerg. Microbes Infect.2019874975910.1080/22221751.2019.161488531130109 44.De"/>
 <result pre="RNA chain terminatorsHandb. Exp. Pharmacol.2009538410.1007/978-3-540-79086-0_319048197 45.EyerL.NenckaR.HuvarovaI.PalusM.Joao AlvesM.GouldE.A.De ClercqE.RuzekD.Nucleoside Inhibitors of" exact="Zika" post="VirusJ. Infect. Dis.201621470771110.1093/infdis/jiw22627234417 46.HercikK.KozakJ.SalaM.DejmekM.HrebabeckyH.ZbornikovaE.SmolaM.RuzekD.NenckaR.BouraE.Adenosine triphosphate analogs can efficiently inhibit"/>
 <result pre="VirusJ. Infect. Dis.201621470771110.1093/infdis/jiw22627234417 46.HercikK.KozakJ.SalaM.DejmekM.HrebabeckyH.ZbornikovaE.SmolaM.RuzekD.NenckaR.BouraE.Adenosine triphosphate analogs can efficiently inhibit the" exact="Zika" post="virus RNA-dependent RNA polymeraseAntivir. Res.201713713113310.1016/j.antiviral.2016.11.02027902932 47.ZmurkoJ.MarquesR.E.ScholsD.VerbekenE.KapteinS.J.NeytsJ.The Viral Polymerase Inhibitor"/>
 <result pre="Polymerase Inhibitor 7-Deaza-2’-C-Methyladenosine Is a Potent Inhibitor of In Vitro" exact="Zika" post="Virus Replication and Delays Disease Progression in a Robust"/>
 <result pre="infectionsAntivir. Res.2009829510210.1016/j.antiviral.2009.02.19819428599 51.BazM.GoyetteN.GriffinB.D.KobingerG.P.BoivinG.In vitro susceptibility of geographically and temporally distinct" exact="Zika" post="viruses to favipiravir and ribavirinAntivir. Ther.20172261361810.3851/IMP318028694390 52.CaiL.SunY.SongY.XuL.BeiZ.ZhangD.DouY.WangH.Viral polymerase inhibitors"/>
 <result pre="52.CaiL.SunY.SongY.XuL.BeiZ.ZhangD.DouY.WangH.Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of" exact="Zika" post="virus replicationArch. Virol.20171622847285310.1007/s00705-017-3436-828597088 53.DelangL.AbdelnabiR.NeytsJ.Favipiravir as a potential countermeasure against"/>
 <result pre="virusesAntivir. Res.2018153859410.1016/j.antiviral.2018.03.00329524445 54.DengY.Q.ZhangN.N.LiC.F.TianM.HaoJ.N.XieX.P.ShiP.Y.QinC.F.Adenosine Analog NITD008 Is a Potent Inhibitor of" exact="Zika" post="VirusOpen Forum Infect. Dis.20163ofw17510.1093/ofid/ofw17527747251 55.MunjalA.KhandiaR.DhamaK.SachanS.KarthikK.TiwariR.MalikY.S.KumarD.SinghR.K.IqbalH.M.N.et al.Advances in Developing Therapies"/>
 <result pre="Forum Infect. Dis.20163ofw17510.1093/ofid/ofw17527747251 55.MunjalA.KhandiaR.DhamaK.SachanS.KarthikK.TiwariR.MalikY.S.KumarD.SinghR.K.IqbalH.M.N.et al.Advances in Developing Therapies to Combat" exact="Zika" post="Virus: Current Knowledge and Future PerspectivesFront. Microbiol.20178146910.3389/fmicb.2017.0146928824594 56.ReznikS.E.AshbyC.R.Jr.Sofosbuvir: An"/>
 <result pre="PerspectivesFront. Microbiol.20178146910.3389/fmicb.2017.0146928824594 56.ReznikS.E.AshbyC.R.Jr.Sofosbuvir: An antiviral drug with potential efficacy against" exact="Zika" post="infectionInt. J. Infect. Dis.201755293010.1016/j.ijid.2016.12.01127988410 57.Bullard-FeibelmanK.M.GoveroJ.ZhuZ.SalazarV.VeselinovicM.DiamondM.S.GeissB.J.The FDA-approved drug sofosbuvir inhibits"/>
 <result pre="Zika infectionInt. J. Infect. Dis.201755293010.1016/j.ijid.2016.12.01127988410 57.Bullard-FeibelmanK.M.GoveroJ.ZhuZ.SalazarV.VeselinovicM.DiamondM.S.GeissB.J.The FDA-approved drug sofosbuvir inhibits" exact="Zika" post="virus infectionAntivir. Res.201713713414010.1016/j.antiviral.2016.11.02327902933 58.SacramentoC.Q.de MeloG.R.de FreitasC.S.RochaN.HoelzL.V.MirandaM.Fintelman-RodriguesN.MarttorelliA.FerreiraA.C.Barbosa-LimaG.et al.The clinically approved"/>
 <result pre="58.SacramentoC.Q.de MeloG.R.de FreitasC.S.RochaN.HoelzL.V.MirandaM.Fintelman-RodriguesN.MarttorelliA.FerreiraA.C.Barbosa-LimaG.et al.The clinically approved antiviral drug sofosbuvir inhibits" exact="Zika" post="virus replicationSci. Rep.201774092010.1038/srep4092028098253 59.PeralesC.DomingoE.Antiviral Strategies Based on Lethal Mutagenesis"/>
 <result pre="and Error ThresholdCurr. Top. Microbiol. Immunol.201639232333926294225 60.LazearH.M.GoveroJ.SmithA.M.PlattD.J.FernandezE.MinerJ.J.DiamondM.S.A Mouse Model of" exact="Zika" post="Virus PathogenesisCell Host Microbe20161972073010.1016/j.chom.2016.03.01027066744 61.MangiaA.PiazzollaV.Overall efficacy and safety results"/>
 <result pre="5S179S18510.1016/j.dld.2014.09.02625458780 62.EyerL.ZouharovaD.SirmarovaJ.FojtikovaM.StefanikM.HaviernikJ.NenckaR.de ClercqE.RuzekD.Antiviral activity of the adenosine analogue BCX4430 against" exact="West Nile" post="virus and tick-borne flavivirusesAntivir. Res.2017142636710.1016/j.antiviral.2017.03.01228336346 63.WarrenT.K.WellsJ.PanchalR.G.StuthmanK.S.GarzaN.L.Van TongerenS.A.DongL.RettererC.J.EatonB.P.PegoraroG.et al.Protection against"/>
 <result pre="BCX4430Nature201450840240510.1038/nature1302724590073 64.JulanderJ.G.SiddharthanV.EvansJ.TaylorR.TolbertK.ApuliC.StewartJ.CollinsP.GebreM.NeilsonS.et al.Efficacy of the broad-spectrum antiviral compound BCX4430 against" exact="Zika" post="virus in cell culture and in a mouse modelAntivir."/>
 <result pre="in a mouse modelAntivir. Res.2017137142210.1016/j.antiviral.2016.11.00327838352 65.StephenP.BazM.BoivinG.LinS.X.Structural Insight into NS5 of" exact="Zika" post="Virus Leading to the Discovery of MTase InhibitorsJ. Am."/>
 <result pre="Versatile Tools for SAM-Dependent MethyltransferasesACS Chem. Biol.20161158359710.1021/acschembio.5b0081226540123 68.HercikK.BryndaJ.NenckaR.BouraE.Structural basis of" exact="Zika" post="virus methyltransferase inhibition by sinefunginArch. Virol.20171622091209610.1007/s00705-017-3345-x28357511 69.Robert-GeroM.LawrenceF.LedererE.Potential Clinical Use"/>
 <result pre="of novel small molecule inhibitors against NS2B/NS3 serine protease from" exact="Zika" post="virusAntivir. Res.2017139495810.1016/j.antiviral.2016.12.01628034741 71.BahramsoltaniR.SodagariH.R.FarzaeiM.H.AbdolghaffariA.H.GoosheM.RezaeiN.The preventive and therapeutic potential of natural"/>
 <result pre="the Natural Polyphenols Delphinidin and Epigallocatechin Gallate against the Flaviviruses" exact="West Nile" post="Virus, Zika Virus, and Dengue VirusFront. Microbiol.20178131410.3389/fmicb.2017.0131428744282 73.WuY.H.Naturally derived"/>
 <result pre="Delphinidin and Epigallocatechin Gallate against the Flaviviruses West Nile Virus," exact="Zika" post="Virus, and Dengue VirusFront. Microbiol.20178131410.3389/fmicb.2017.0131428744282 73.WuY.H.Naturally derived anti-hepatitis B"/>
 <result pre="Gallate against the Flaviviruses West Nile Virus, Zika Virus, and" exact="Dengue" post="VirusFront. Microbiol.20178131410.3389/fmicb.2017.0131428744282 73.WuY.H.Naturally derived anti-hepatitis B virus agents and"/>
 <result pre="virus and their structure activity relationshipBiotechnol. Lett.20173941542110.1007/s10529-016-2261-627885509 75.RoyA.LimL.SrivastavaS.LuY.SongJ.Solution conformations of" exact="Zika" post="NS2B-NS3pro and its inhibition by natural products from edible"/>
 <result pre="ONE201712e018063210.1371/journal.pone.018063228700665 76.LiZ.BrecherM.DengY.Q.ZhangJ.SakamuruS.LiuB.HuangR.KoetznerC.A.AllenC.A.JonesS.A.et al.Existing drugs as broad-spectrum and potent inhibitors for" exact="Zika" post="virus by targeting NS2B-NS3 interactionCell Res.2017271046106410.1038/cr.2017.8828685770 77.YuanS.ChanJ.F.den-HaanH.ChikK.K.ZhangA.J.ChanC.C.PoonV.K.YipC.C.MakW.W.ZhuZ.et al.Structure-based discovery"/>
 <result pre="interactionCell Res.2017271046106410.1038/cr.2017.8828685770 77.YuanS.ChanJ.F.den-HaanH.ChikK.K.ZhangA.J.ChanC.C.PoonV.K.YipC.C.MakW.W.ZhuZ.et al.Structure-based discovery of clinically approved drugs as" exact="Zika" post="virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus"/>
 <result pre="drugs as Zika virus NS2B-NS3 protease inhibitors that potently inhibit" exact="Zika" post="virus infection in vitro and in vivoAntivir. Res.2017145334310.1016/j.antiviral.2017.07.00728712942 78.AguilarJ.S.RiceM.WagnerE.K.The"/>
 <result pre="high throughput assay formatBiochem. Biophys. Res. Commun.201445353954410.1016/j.bbrc.2014.09.11325281902 85.AlbulescuI.C.KovacikovaK.TasA.SnijderE.J.van HemertM.J.Suramin inhibits" exact="Zika" post="virus replication by interfering with virus attachment and release"/>
 <result pre="Virol.200616374810.1002/rmv.48316287208 88.SidwellR.W.HuffmanJ.H.KhareG.P.AllenL.B.WitkowskiJ.T.RobinsR.K.Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamideScience197217770570610.1126/science.177.4050.7054340949 89.KamiyamaN.SomaR.HidanoS.WatanabeK.UmekitaH.FukudaC.NoguchiK.GendoY.OzakiT.SonodaA.et al.Ribavirin inhibits" exact="Zika" post="virus (ZIKV) replication in vitro and suppresses viremia in"/>
 <result pre="STAT1-deficient miceAntivir. Res.201714611110.1016/j.antiviral.2017.08.00728818572 90.TongX.SmithJ.BukreyevaN.KomaT.ManningJ.T.KalkeriR.KwongA.D.PaesslerS.Merimepodib, an IMPDH inhibitor, suppresses replication of" exact="Zika" post="virus and other emerging viral pathogensAntivir. Res.2018149344010.1016/j.antiviral.2017.11.00429126899 91.RauschK.HackettB.A.WeinbrenN.L.ReederS.M.SadovskyY.HunterC.A.SchultzD.C.CoyneC.B.CherryS.Screening Bioactives"/>
 <result pre="Bioactives Reveals Nanchangmycin as a Broad Spectrum Antiviral Active against" exact="Zika" post="VirusCell Rep.20171880481510.1016/j.celrep.2016.12.06828099856 92.BarrowsN.J.CamposR.K.PowellS.T.PrasanthK.R.Schott-LernerG.Soto-AcostaR.Galarza-MunozG.McGrathE.L.Urrabaz-GarzaR.GaoJ.et al.A Screen of FDA-Approved Drugs for"/>
 <result pre="Rep.20171880481510.1016/j.celrep.2016.12.06828099856 92.BarrowsN.J.CamposR.K.PowellS.T.PrasanthK.R.Schott-LernerG.Soto-AcostaR.Galarza-MunozG.McGrathE.L.Urrabaz-GarzaR.GaoJ.et al.A Screen of FDA-Approved Drugs for Inhibitors of" exact="Zika" post="Virus InfectionCell Host Microbe20162025927010.1016/j.chom.2016.07.00427476412 93.PascoalinoB.S.CourtemancheG.CordeiroM.T.GilL.H.Freitas-JuniorL.Zika antiviral chemotherapy: Identification of"/>
 <result pre="chloroquineAm. J. Perinatol.1991817417810.1055/s-2007-9993712029276 101.DelvecchioR.HigaL.M.PezzutoP.ValadaoA.L.GarcezP.P.MonteiroF.L.LoiolaE.C.DiasA.A.SilvaF.J.AliotaM.T.et al.Chloroquine, an Endocytosis Blocking Agent, Inhibits" exact="Zika" post="Virus Infection in Different Cell ModelsViruses2016832210.3390/v8120322 102.MinerJ.J.CaoB.GoveroJ.SmithA.M.FernandezE.CabreraO.H.GarberC.NollM.KleinR.S.NoguchiK.K.et al.Zika Virus"/>
 <result pre="Damage and Fetal DemiseCell20161651081109110.1016/j.cell.2016.05.00827180225 103.KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.De BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and gemcitabine inhibit" exact="Zika" post="virus infection in vitro and differentially affect cellular signaling,"/>
 <result pre="broad antiviral effectsPLoS Pathog.20128e100297610.1371/journal.ppat.100297623133371 105.XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.et al.Identification of small-molecule inhibitors of" exact="Zika" post="virus infection and induced neural cell death via a"/>
 <result pre="SartoJ.L.RochaR.F.SilvaF.R.DoriaJ.G.OlmoI.G.MarquesR.E.Queiroz-JuniorC.M.FoureauxG.AraujoJ.M.S.et al.N-Methyl-d-Aspartate (NMDA) Receptor Blockade Prevents Neuronal Death Induced by" exact="Zika" post="Virus InfectionmBio2017810.1128/mBio.00350-1728442607 Figure 1 Detailed structure of Zika virus"/>
 <result pre="Induced by Zika Virus InfectionmBio2017810.1128/mBio.00350-1728442607 Figure 1 Detailed structure of" exact="Zika" post="virus (ZIKV) genome. ZIKV genomic RNA is capped but"/>
 <result pre="InfectionmBio2017810.1128/mBio.00350-1728442607 Figure 1 Detailed structure of Zika virus (ZIKV) genome." exact="ZIKV" post="genomic RNA is capped but lacks poly A tail."/>
 <result pre="NS2A, NS2B, NS3, NS4A, 2K, NS4B, and NS5). Figure 2" exact="Zika" post="virus life cycle. ZIKV, an enveloped RNA virus, enters"/>
 <result pre="pharmaceuticals-12-00101-t001_Table 1Table 1 The table shows the structural and nonstructural" exact="ZIKV" post="proteins from the 5’ to the 3’ untranslated regions."/>
 <result pre="reductase inhibitor √ X Azithromycin Unknown mechanisms of action against" exact="ZIKV" post="√ X Chloroquine Inhibition of pH-dependent steps of viral"/>
</results>
